Heme oxygenase and indoleamine regulation by cytokines in cervical cancer cells and natural killer cells cytotoxic activity

Pablo C. Ortiz-Lazareno¹, Paulina Gómez-Lomeli¹, Georgina Hernández-Flores¹, Cristina Rodríguez-Padilla², Francisco Javier Ochoa-Carrillo³ and Alejandro Bravo-Cuellar¹,4,*

¹Immunology Division, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara, Jal.; ²Faculty of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, N.L.; ³Surgical oncologist, Instituto Nacional de Cancerología de México, Ciudad de México; ⁴Department of Health Sciences, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos, Jal. Mexico

Abstract

Objective: To determine the effect of the cytokines interleukin (IL-4), IL-10, Interferon gamma (IFN-γ) and tumor necrosis factor (TNF-α) in protein expression of HO-1 and IDO in cervical cancer cell lines and the cytotoxicity of NK cells in co-culture with cervix cancer cells pretreated with HO-1 and IDO inhibitors. Methods: The cervical cancer cell lines HeLa (HPV 18+), SiHa (HPV 16+) and C-33A (HPV -) were treated with 20 ng/mL of IL-4, IL-10, IFN-γ and TNF-α for 3 h, 6 h and 12 h, after that protein expression was assessed by flow cytometry. The cytotoxic activity of NK cells was performed in real time for 4 h. Results: Protein expression of the enzymes were changed at early times, increasing the expression of the enzymes in the 3 cell lines. We observed an increase in cytotoxic activity of NK cells cocultured with HeLa cells pretreated with the HO-1 inhibitor and in SiHa cells pretreated with the IDO inhibitor. Conclusion: The suppressor enzyme IDO is positively regulated by IL-10 in HeLa, SiHa, and NK cytotoxic activity increase in Hela and SiHa cells pretreated with HO-1 and IDO inhibitors respectively, which could be part of tumor escape mechanisms in cervix cancer.

Key words: Indoleamine. Histidine decarboxilase. Cervix cancer. Cytokines. NK cells.
Introduction

Cervical cancer is the second most common cancer in women of developing countries\(^1\),\(^2\). The main risk factor for the development of this cancer is human papillomavirus (HPV) infection\(^3\),\(^4\). Although HPV infection does not induce an acute inflammatory response, an increased expression of cytokines such as TNF-\(\alpha\) and IL-1 has been observed in patients with high and low grade lesions, as well as with cervical cancer\(^5\).

A T-helper (TH1) response might be important in eliminating the virus, since it enhances cell response by means of the production of IL-2 and IFN-\(\gamma\). TH2 response increases humoral immunity and, in consequence, IL-4 and IL-10 are released\(^6\). However, a TH2 response can produce an inadequate control of HPV infectious process, since IL-2 decreased expression and an increase in IL-4 have been found in high-grade lesions\(^7\), in addition to IL-10 overexpression in high-grade lesions when compared with low-grade lesions and normal cervical tissue\(^8\),\(^9\).

In HPV-associated lesions, both dendritic cells and myeloid stromal cells have been found to express the indoleamine (IDO) enzyme, which is known for its role in suppressor T-cell induction, which might contribute to the immunosuppression of immune system cells present in the tumor microenvironment, such as natural killer (NK) cells\(^10\), and facilitate tumor growth.

Indoleamine is the enzyme in charge to catabolize tryptophan, and it is encoded by a gene located in chromosome 8p12. In 1990, Munn DH, Mellor AL, et al. reported that IDO activity is essential in mice to prevent maternal allogeneic rejection of the fetus due to T cell-mediated immunity. Subsequent studies have widely broadened IDO immunosuppressant role in a variety of chronic infections, including viral, parasitic and bacterial infections in the human being\(^11\),\(^12\).

IDO has been reported to be overexpressed in cervical cancer and cervical adenocarcinoma cells, whereas adjacent stromal cells lack such expression. In contrast, it is not expressed in cervical squamous epithelium or endocervical glands\(^13\).

Heme oxygenase-1 (HO-1) is the main enzyme implicated in heme group catabolism and gives rise to three fundamental products: biliverdin, free iron and carbon monoxide\(^14\). It plays an important role in the modulation of inflammatory processes and in the antioxidant defense mechanisms the body possesses when there is any damage present and in the blockage of apoptotic processes\(^15\),\(^16\). This enzyme is overexpressed in pancreatic, colon and lung cancer, where it favors tumor proliferation and anti-tumor therapy resistance\(^17\),\(^18\). HO-1 induction in tumor cells subjected to any stressor agent increases its resistance to apoptosis. Furthermore, inhibition of this enzyme leads to tumor growth reduction and to an increase in sensitivity to chemotherapy\(^19\). In our laboratory we observed that, in NK cells co-cultured with cervical cancer cells previously treated with a HO-1 specific inhibitor, the production of IFN-\(\gamma\) and TNF-\(\alpha\) by NK cells was increased in comparison with those that were in contact with cell lines without treatment\(^20\).

However, the effect cytokines such as IL-4, IL-10, TNF-\(\alpha\) and IFN-\(\gamma\) may have on IDO and HO-1 expression in cervical cancer cell lines is not known, as neither is NK cells cytotoxic activity in cervical cancer cells previously treated with these inhibitors.

Materials and methods

Cell culture

The HeLa (HPV 18\(+\)), SiHa (HPV 16\(+\)), C-33A (HPV-\(-\)) cell lines were donated by P. Boukamp (DKFZ Heidelberg, Germany), preserved in DMEM medium (Gibco, Life Technologies, Grand Island, New York, USA) supplemented with 10% of LPS-free fetal bovine serum (Gibco), 100 U of penicillin and 100 \(\mu\)g of streptomycin per each medium milliliter, 1% L-glutamine and 80 U/mL of IL-2 (Biolegend, San Diego, CA, USA). All cell lines were incubated at 37 °C in a humid atmosphere with 5% CO\(_2\).

To determine IDO and HO-1 enzymes expression, the cervical cancer cell lines were seeded in p-100 plates (1 \(\times\) 10\(^5\) cells per plate), and were treated with TNF-\(\alpha\), IFN-\(\gamma\) (Biolegend), IL-10 or IL-4 (eBioscience, San Diego, CA, USA) at a 20 ng/mL concentration, in supplemented DMEM culture medium for 3, 6 and 12 h at 37 °C and with 5% CO\(_2\).

The HeLa, SiHa and C-33A tumor cell lines were seeded in culture flasks and were separately treated with tin protoporphyrin IX (SnPP; Frontier Scientific, Inc. Logan, UT, USA), HO-1 inhibitor at a 25 \(\mu\)M concentration and 1-L-methyltryptophan (1-MT; Sigma-Aldrich), IDO inhibitor, at a concentration of 2.5 mM, both for 48 h.
**Indoleamine and heme oxygenase 1 enzymes evaluation**

Once treatments with the cytokines were completed, the cancer cell lines were washed with PBS (Gibco) and fixed with fixative solution (Biolegend) for 20 min. After a wash with permeating solution (Biolegend), permeability was induced with this solution for 5 min. The cells were marked with the primary antibodies: mouse anti-human HO-1 (abcam, Cambridge, MA, USA) and mouse anti-human IDO-1 (AbD serotec, Oxford, United Kingdom) for 30 min. Subsequently, the cells were incubated with the secondary antibodies: goat anti-mouse immunoglobulin G (IgG) coupled with fluorescein isothiocyanate (FITC; abcam) and rabbit anti-mouse IgG coupled with phycoerythrin (PE; AbD serotec), for 30 min, protected from light. After incubation with the antibodies, the cells were washed with PBS, fixed with 0.5% paraformaldehyde (Sigma) in PBS and were analyzed in the flow cytometer EPICS-XL (Beckman Coulter Corp.). Data were analyzed using the WINMDI software, version 2.9. At least 20,000 events were acquired for each sample. Mean fluorescence intensity expression percentage and geometric mean of all experimental groups were obtained. Data were represented as the expression percentage mean.

**Cell death real-time evaluation**

Five-thousand tumor cells, pre-treated or not with HO-1 and IDO enzymes specific inhibitors, were seeded in a 96-well plate (E-plate; Roche), following the xCELLigence Real Time Cell Analyzer (RTCA; Roche) manual instructions; NK cells were added in sufficient amount to cover the target: effector range at 1:20, and the co-culture was maintained for 4 h.

The normalized cell index (nCl) was obtained with the RTCA software, and based on it, the percentage of lysis was calculated using the formula: lysis % = [nCl (non-effector) x nCl (effector)]/nCl (non-effector) x 100. The results are expressed as the average of at least three independent experiments performed in triplicate.

**Statistical analysis**

For statistical analysis, the means and standard deviation of at least three observations were obtained in triplicate for each one of the groups. Data were analyzed using the non-parametric Mann-Whitney U-test. Values with a p-value ≤ 0.05 were considered to be significantly different.

**Results**

Interferon γ, TNF-α, IL-4 and IL-10 reduce HO-1 expression in cervical cancer cell lines: to assess the effect of the treatment with cytokines on HO-1 expression, the HeLa, SiHa and C-33A lines were treated with 20 ng/mL of IL-4, IL-10, IFN-γ and TNF-α for 3, 6 and 12 h. HO-1 expression in HeLa did significantly decrease (p < 0.05) since 3 h of treatment with IFN-γ and TNF-α, while IL-4 and IL-10 induced an expression decrease at 12 h of treatment (Fig. 1).

In SiHa, only the treatment with IFN-γ induced modifications in the expression of the enzyme, since it increased it 3 and 6 h (p < 0.05) after the cytokine was added. In C-33A, IFN-γ increased HO-1 enzyme expression at 6 h of treatment, whereas TNF-α induced an increase in the enzyme expression at 3 h, with this increase being maintained up to the 6 h time point in comparison with untreated cells.

IDO expression in cervical cancer cell lines is increased for short periods of treatment with the cytokines. Figure 2 shows the graphs of the IDO enzyme protein expression after treatment with the cytokines for 3, 6 and 12 h. IDO expression is increased in HeLa and SiHa at 3 h, and in C-33A at 12 h of treatment with IL-4. However, in general, there are no significant changes in the cervical cancer cell lines with regard to baseline levels observed in these cell lines. When SiHa and C-33A were treated with IL-10, IDO expression was significantly increased at 3 h of treatment (p < 0.05).

Treatment with IFN-γ induces an increase in the expression of the enzyme in HeLa cells during the first 3 h (p < 0.05), and it decreases progressively over time until an expression similar to that of the baseline group is reached. In SiHa, an IDO enzyme increase is observed from 6 and 12 h on (p < 0.05). The cervical cancer cells were treated with TNF-α, and an IDO expression increase is observed in SiHa and C-33A at 3 and 12 h (p < 0.05).

Assessment of NK-mediated cytotoxicity in tumor cells treated with HO-1 (SnPP) and IDO (1-MT) inhibitors, in order to assess the participation of HO-1 and IDO expressed by cervical cancer cell lines in the resistance to NK cells cytotoxic activity: the tumor cells were pretreated with specific inhibitors of these enzymes and co-culture with NK cells was subsequently carried out, with NK cell-mediated cell lysis being evaluated in real time. Figure 3 shows the percentage of NK cell-mediated lysis of the HeLa, SiHa and C-33A lines. HO-1 inhibition in the tumor cell lines favored an increase in the percentage of lysis, which was
Figure 1. HO-1 expression kinetics. The HeLa, SiHa and C-33A cervical cancer cell lines were treated with: A) IL-4, B) IL-10, C) IFN-γ and D) TNF-α for 3, 6 and 12 h. The bars represent the standard error of the mean. Time 0 is regarded as the baseline expression (*p < 0.05).

Figure 2. DO1 enzyme expression kinetics. HeLa, SiHa and C-33A were treated for 3, 6 and 12 h with: A) IL-4, B) IL-10, C) IFN-γ and D) TNF-α. The bars represent the standard error of the mean. Time 0 is regarded as the baseline expression (*p < 0.05).
significant in HeLa (HPV 18+). On the other hand, IDO inhibition in the tumor cell lines favored an increase in the percentage of lysis in SiHa cells in comparison with cells not treated with the inhibitor (HPV 16+).

**Discussion**

Immune system cells and the release of their soluble mediators, such as cytokines, can shape tumor cells by favoring changes in order for them to produce molecules they normally would not express and that would enable them to evade apoptosis, proliferate without control and even evade the immune response\textsuperscript{21,22}. The molecules tumor cells can express include certain cytokines (e.g., IL-10 and transforming growth factor beta [TGF-\(\beta\)]), chemokines such as CC chemokine receptor type 2 (CCR2) or enzymes such as IDO and HO-1\textsuperscript{23,24}. HO-1 and DOI overexpression has been reported in different types of cancer, including cervical cancer\textsuperscript{20,25,26}. Regulation mechanisms of these enzymes range from transcription factors, which are activated by external stimuli, to products of enzyme activity\textsuperscript{27}. IDO expression in response to cytokines is dependent on the cell type\textsuperscript{28}, as it also is in the case of HO-1. For example, IFN-\(\gamma\) has been reported to suppress HO-1 expression in human glioblastoma cell lines, while TNF-\(\alpha\) has no effect on the expression of this enzyme\textsuperscript{29}. These variations were observed in our study, where, in spite of the three cervical cancer cell lines being epithelial cells, the response to the cytokines was different for each one of them.

In the HO-1 expression in the SiHa cell line, we may probably have observed a redundancy phenomenon between cytokines, since the enzymes’ expression variation in time is the same for all four cytokines. IFN-\(\gamma\) induces an increase in IDO expression in the HeLa and SiHa cervical cancer cell lines during the first hours of treatment; in C-33A, the expression increases until 12 h. In different types of cells, IFN-\(\gamma\) is able to induce IDO expression\textsuperscript{30-32}. In HLE-B3 epithelial cell lines, IDO enzyme activity increases proportionally to IFN-\(\gamma\) concentration\textsuperscript{33}.

Particularly in SiHa, TNF-\(\alpha\) induces an IDO expression increase. With regard to TNF-\(\alpha\), it has not been observed to have any effect on the expression of this enzyme\textsuperscript{32,34,35}; however, it is able to potentiate its expression when combined with other pro-inflammatory cytokines\textsuperscript{30,32}. In our study, we found that TNF-\(\alpha\) induces expression changes, regardless of the cell type.

With regard to IL-10, this cytokine induces an increase in IDO expression during the first 12 h in the three cervical cancer cell lines, with this induction being lower in HeLa cells. In other studies, IL-10 has been reported to increase IDO enzyme expression in regulatory T cells\textsuperscript{36,37}.

Based in our observations, HO-1 plays a protective role in HeLa (HPV 18+) cells, since when this enzyme is inhibited, NK cells cytotoxic activity is increased, while the IDO enzyme protects SiHa (HPV 16+) tumor cells from NK cells cytotoxicity. This is interesting, since it indicates there are different mechanisms to evade the immune response, particularly the response exerted by NK cells, as demonstrated in this study. These
mechanisms are probably related to HPV infection and types, since in the HPV-negative C-33A line, these differences were not observed.

It should be highlighted that the changes observed in our study in the expression of the enzymes when challenged with cytokines occurred in short periods of treatment owing to the fact that these are stress-response enzymes, which confers a protecting role to the cells that express them. Interestingly, this protecting role was confirmed when both HO-1 and IDO were inhibited, and the cells became more sensitive to NK cell-mediated cell death.

Conclusions

The HO-1 enzyme expression decreases when tumor cells are treated with different cytokines, and other cytokines or molecules may therefore be involved in its regulation. This may have important implications for the development of strategies to treat cancer by enhancing the immune response against tumors.

Acknowledgements

To the Fondo de Investigación en Salud, for the FIS/IMSS/PROT/508 funding granted for the performance of this study, and to Red Temática del CONACYT de Inmunología en Cáncer y Enfermedades Infecciosas INMUNOCANEI-CONACYT No. 280135.

Conflict of interests

The authors declare not having any conflicts of interests.

References